Our vision is to fundamentally transform prenatal diagnostics by making cell-free non-invasive prenatal testing (cfNIPT), chorionic villus sampling (CVS) and amniocentesis (Amnio) obsolete.
Our vision is to fundamentally transform prenatal diagnostics by making cell-free non-invasive prenatal testing (cfNIPT), chorionic villus sampling (CVS) and amniocentesis (Amnio) obsolete.
If you are pregnant
ARCEDI’s prenatal tests can give you peace of mind concerning your future child. Learn more about EVITA TEST COMPLETE at evitatest.com
TECHNOLOGY
ARCEDI’s unique technology isolates fetal cells from maternal blood and uses them for genetic analysis
PRODUCT
With ‘EVITA TEST COMPLETE’ ARCEDI is the first company to provide genome-wide analysis of the fetus using circulating fetal cells
PATENTS
ARCEDI’s strong IP portfolio covers four patents and provides global protection through 2031
Latest news
Novel and High‐Throughput Method of Isolating Single Fetal Cells Using FACS for NIPT
Abstract: Objective: To evaluate fluorescence activated cell sorting (FACS) as a method of single‐cell isolation of rare circulating fetalcells from maternal blood for use in
Exploring fetal cells in maternal blood in relation to rupture of the fetal membranes
Abstract:Introduction: Cellular derangements contributing to fetal membrane damage precede spontaneous rupture at term and are even more pronounced in preterm prelabor rupture of membranes. We
mRNA and Protein Expression in Human Fetal Membrane Cells: Potential Biomarkers for Preterm Prelabor Rupture of the Fetal Membranes?
Abstract: Clinically, unique markers in fetal membrane cells may contribute to the search for biomarkers for preterm prelabor rupture of the fetal membranes (pPROM) in
Newsletter
Subscribe to our newsletter to get the latest updates on products and new scientific publications on ARCEDI technology.
